Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Selitrectinib Formulations in Healthy Adults
NCT04771390Phase 1Completed
- Sponsor
- Bayer
- Start
- Feb 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of selitrectinib in NTRK fusion-positive solid tumors (9 arms), sponsored by Bayer. Primary endpoints: Area Under the Plasma Concentration-Time Curve at 48 hours, Area Under the Plasma Concentration-Time Curve from 0 to 24 hours and 1 more. Started Feb 2021; status: completed.
02
Drugs
selitrectinib
03
Conditions
NTRK fusion-positive solid tumors
Beyond the preview
Go deeper on NCT04771390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04771390.